16.1.5.1 SPONSOR

CLINICAL STUDY REPORT APPROVAL FORM

PROTOCOL NUMBER: C4591001

REPORT TITLE: Final Analysis Interim Report: A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

AUTHOR: Dzung Nguyen

I have reviewed this clinical study report, which is from its definitive source and final in content. I confirm that it is a complete and accurate representation of the relevant data and statistical analyses for this report.

Known deviations in the study did not impact overall compliance with Good Clinical Practice and local regulations.

Organization/Institution: BioNTech

Name/Position: Ugur Sahin, MD, Chief Executive Officer

Signature:_____ **Date:** 3. 12. 2020

16.1.5.1 SPONSOR AGENT

CLINICAL STUDY REPORT APPROVAL FORM

PROTOCOL NUMBER: C4591001

REPORT TITLE: Final Analysis Interim Report: A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

AUTHOR: Dzung Nguyen

I have reviewed this clinical study report, which is from its definitive source and final in content. I confirm that it is a complete and accurate representation of the relevant data and statistical analyses for this report.

Known deviations in the study did not impact overall compliance with Good Clinical Practice and local regulations.

STATISTICS LINE HEAD: **Kenneth Koury, PhD**

CLINICAL LEAD: **John L. Perez, MD, MBA, MA**

Document Approval Record

Document Name:	16.1.5.1 - Sponsor Agent
Document Title:	C4591001 FA

Signed By:	Date(GMT)	Signing Capacity
Perez, John	03-Dec-2020 12:46:50	Final Approval
Koury, Kenneth	03-Dec-2020 14:12:20	Final Approval